Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 2Phase 3 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 7Dermatologic 7Head & Neck 6Tumor-Agnostic 5Lymphoid 5Gynecologic 4Genitourinary 4Breast 4Plasma cell 2Other solid neoplasm 2Gastrointestinal 2Endocrine 2CNS 2Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Gliosarcoma 1Glioblastoma 1

Interventions

Temozolomide 62Cyclophosphamide 60Radiotherapy 48Doxorubicin 36Filgrastim 26Radiation 24Irinotecan 24fludarabine 23Gemcitabine 23Magnetic Resonance Spectroscopy 21Imatinib Mesylate 19Etoposide 18pembrolizumab 16Cisplatin 15Carboplatin 15Biopsy 15Bevacizumab 15Specimen Handling 14fludarabine phosphate 12Nivolumab 12Leucovorin 12Ipilimumab 12Granulocyte Colony-Stimulating Factor 12Chemotherapy, Adjuvant 12pazopanib 11Vincristine 11Ifosfamide 11Melphalan 10Erlotinib Hydrochloride 10Docetaxel 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × cemiplimab × Sarcoma × Clear all
NCT07422363 2026-05-13

Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
30 enrolled
CNSSarcoma

Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡